Table 2.

Clinical response (SLEDAI) to treatment at weeks 12 and 24: interim analysis in the target population

	Lupuzor
	Group 1 (200 μg every 4 weeks)	Group 2 (200 μg every 2 weeks)	Group 3 (placebo)
Week 12	n=34	n=39	n=41
Responders, n (%)	23 (67.6)	20 (51.3)	17 (41.5)
	p<0.025	p=0.19	–
Week 24	n=19	n=21	n=24
Responders, n (%)	16 (84.2)	14 (66.7)	11 (45.8)
	p<0.025	p=0.15	–

p Values compare Lupuzor with placebo. Drop-outs are considered as non-responders. All data available at the cut-off date are presented.

SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.